专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07834182B2 Piperidine derivative 失效
标题翻译：哌啶衍生物
公开(公告)号：US07834182B2
公开(公告)日：2010-11-16
申请号：US12381099
申请日：2009-03-06
申请人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Mizutani
发明人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Mizutani
IPC分类号： C07D401/14 , C07D403/14 , A61K31/4545 , A61K31/496 , A61K31/454 , A61K31/4523 , A61K31/506 , A61P3/04 , A61P3/10 , C07D401/12 , C07D401/02 , C07D401/06
CPC分类号： C07D211/58 , A61K31/454
摘要： Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently resent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.
摘要翻译：提供组胺H3受体拮抗剂; 代谢系统疾病如肥胖症，糖尿病，激素分泌障碍，高脂血症，痛风，脂肪肝，循环系统疾病，例如心动过速，急性/充血性心功能不全，心肌梗塞，冠状动脉硬化等的预防和/或补救措施，高血压，肾病，睡眠障碍和伴有睡眠障碍的各种疾病，例如特发性睡眠过多，重度睡眠过多，睡眠周期性运动障碍，睡眠呼吸暂停综合征，昼夜节律紊乱，慢性疲劳综合征，REM睡眠障碍，老年性失眠，夜间工人睡眠躁狂，特发性失眠，重复性失眠，真实失眠，电解质代谢紊乱; 注意力缺陷/多动症，记忆障碍，阿尔茨海默氏病，帕金森病，睡眠障碍，识别障碍，运动障碍，中枢神经系统疾病和中枢神经系统疾病如贪食症，情绪障碍，忧郁症，焦虑症，癫痫，del妄，感觉异常，dysosmia，癫痫，吗啡抵抗，麻醉依赖，酒精依赖。组胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH; Y表示特定组; X3表示Os-（CH2）m; R1和R2分别独立地表示氢原子，卤素原子，直链或支链低级烷基，低级烷氧基或被2或3个氟原子取代的乙酰基; s为0或1; 和m是使（m + s）0或1至4]的整数]或其药学上可接受的盐。

2. 发明授权

US07547693B2 Piperidine derivative 失效
标题翻译：哌啶衍生物
公开(公告)号：US07547693B2
公开(公告)日：2009-06-16
申请号：US10574087
申请日：2004-09-21
申请人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Mizutani
发明人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Mizutani
IPC分类号： C07D401/14 , C07D401/12 , C07D401/02 , C07D401/06 , A61K31/4545 , A61K31/496 , A61K31/454 , A61K31/4523 , C07D403/14 , A61K31/506 , A61P3/04 , A61P3/10
CPC分类号： C07D211/58 , A61K31/454
摘要： Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.
摘要翻译：提供组胺H3受体拮抗剂; 代谢系统疾病如肥胖症，糖尿病，激素分泌障碍，高脂血症，痛风，脂肪肝，循环系统疾病，例如心动过速，急性/充血性心功能不全，心肌梗塞，冠状动脉硬化等的预防和/或补救措施，高血压，肾病，睡眠障碍和伴有睡眠障碍的各种疾病，例如特发性超嗜酸症，重复性嗜睡症，真实嗜睡症，发作性睡眠，睡眠周期性运动障碍，睡眠呼吸暂停综合征，昼夜节律紊乱，慢性疲劳综合征，REM睡眠障碍，老年性失眠，夜间工作人员睡眠躁狂，特发性失眠，重复性失眠，真实失眠，电解质代谢障碍，以及中枢和周围神经系统疾病如贪食症，情绪障碍，忧郁症，焦虑症，癫痫，del妄，痴呆，注射缺陷/多动症，记忆障碍，阿尔茨海默病，帕金森病，睡眠障碍，识别障碍，运动障碍，感觉异常，dysosmia，癫痫，吗啡抵抗，麻醉依赖，酒精依赖。组胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH; Y表示特定组; X3表示Os-（CH2）m; R1和R2独立地表示氢原子，卤素原子，直链或支链低级烷基，低级烷氧基或被2或3个氟原子取代的乙酰基; s为0或1; 和m是使（m + s）0或1至4]的整数]或其药学上可接受的盐。

3. 发明申请

US20090203710A1 Novel piperidine derivative 失效
标题翻译：新型哌啶衍生物
公开(公告)号：US20090203710A1
公开(公告)日：2009-08-13
申请号：US12381099
申请日：2009-03-06
申请人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Mizutani
发明人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Mizutani
IPC分类号： A61K31/4545 , C07D401/14 , C07D409/14 , A61K31/496 , A61K31/506 , A61K31/4725 , A61K31/4709
CPC分类号： C07D211/58 , A61K31/454
摘要： Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently resent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.
摘要翻译：提供组胺H3受体拮抗剂; 代谢系统疾病如肥胖症，糖尿病，激素分泌障碍，高脂血症，痛风，脂肪肝，循环系统疾病，例如心动过速，急性/充血性心功能不全，心肌梗塞，冠状动脉硬化等的预防和/或补救措施，高血压，肾病，睡眠障碍和伴有睡眠障碍的各种疾病，如特发性睡眠过度睡眠反复睡眠超声，真正的睡眠过度睡眠，发作性睡眠，睡眠周期性运动障碍，睡眠呼吸暂停综合征，昼夜节律紊乱，慢性疲劳综合征，REM睡眠障碍，老年失眠，夜间工人睡眠躁狂，特发性失眠，重复性失眠，真正失眠，电解质代谢障碍; 注意力缺陷/多动症，记忆障碍，阿尔茨海默氏病，帕金森病，睡眠障碍，识别障碍，运动障碍，中枢神经系统疾病和中枢神经系统疾病如贪食症，情绪障碍，忧郁症，焦虑症，癫痫，del妄，感觉异常，dysosmia，癫痫，吗啡抵抗，麻醉依赖，酒精依赖。组胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH; Y表示特定组; X3表示Os-（CH2）m; R1和R2分别独立地表示氢原子，卤素原子，直链或支链低级烷基，低级烷氧基或被2或3个氟原子取代的乙酰基; s为0或1; 和m是使（m + s）0或1至4]的整数]或其药学上可接受的盐。

4. 发明申请

US20100210637A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE 有权
标题翻译：杂环氧化氮饱和杂环衍生物
公开(公告)号：US20100210637A1
公开(公告)日：2010-08-19
申请号：US12540534
申请日：2009-08-13
申请人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号： A61K31/5377 , C07D403/12 , A61K31/506 , A61P3/10 , A61P3/04 , A61P1/16 , A61P3/06 , A61P9/10 , C07D401/12 , A61K31/4545 , C07D413/14 , A61K31/501
CPC分类号： C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要： Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.
摘要翻译：提供式（I）化合物及其药学上可接受的盐：其中X1，X2和X3各自独立地表示N或CH; W表示下式（II）：或下式（III）：Y表示式（IV）的基团：所述化合物具有组胺H3受体拮抗或反向激动活性，可用于治疗和/或预防肥胖，糖尿病，激素分泌障碍，睡眠障碍等

5. 发明授权

US07595316B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative 有权
标题翻译：杂环氧基含氮饱和杂环衍生物
公开(公告)号：US07595316B2
公开(公告)日：2009-09-29
申请号：US10561115
申请日：2004-06-24
申请人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号： A01N43/58 , A61K31/50 , C07D239/00 , C07D239/02
CPC分类号： C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要： Compound of the formula: (I) [wherein each of X1, X2 and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful of the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep, disorder, etc.
摘要翻译：式（I）的化合物[其中X1，X2和X3各自独立地表示N或CH，W表示式（II）：（II）或式（III）：III），Y表示式（IV）：（IV）]或其药理学上可接受的盐。该化合物显示组胺受体H3拮抗剂或反向激动剂活性，并且可用于治疗和/或预防肥胖症，糖尿病，激素分泌异常，睡眠，障碍等。

6. 发明申请

US20070105901A1 Novel piperidine derivative 失效
公开(公告)号：US20070105901A1
公开(公告)日：2007-05-10
申请号：US10574087
申请日：2004-09-21
申请人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Date
发明人： Norikazu Ohtake , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani , Sayaka Date
IPC分类号： A61K31/4545 , C07D401/14
CPC分类号： C07D211/58 , A61K31/454
摘要： Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

7. 发明授权

US08044070B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative 有权
标题翻译：杂环氧基含氮饱和杂环衍生物
公开(公告)号：US08044070B2
公开(公告)日：2011-10-25
申请号：US12540534
申请日：2009-08-13
申请人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号： A61K31/445 , C07D211/00
CPC分类号： C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要： Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.
摘要翻译：提供式（I）化合物及其药学上可接受的盐：其中X1，X2和X3各自独立地表示N或CH; W表示下式（II）：或下式（III）：Y表示式（IV）的基团：所述化合物具有组胺H3受体拮抗或反向激动活性，可用于治疗和/或预防肥胖，糖尿病，激素分泌障碍，睡眠障碍等

8. 发明申请

US20060178375A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative 有权
标题翻译：杂环氧基含氮饱和杂环衍生物
公开(公告)号：US20060178375A1
公开(公告)日：2006-08-10
申请号：US10561115
申请日：2004-06-24
申请人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人： Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号： A61K31/506 , C07D413/14 , C07D403/14
CPC分类号： C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要： Compound of the formula: (I) [wherein each of X1, X2, and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful of the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep, disorder, etc.
摘要翻译：式（I）的化合物[其中X 1，X 2和X 3各自独立地表示N或CH，W表示式（II）：（II）或式（III）：III），Y表示式（IV）：（IV）]的基团，或其药理学上可接受的盐。该化合物显示组胺受体H3拮抗剂或反向激动剂活性，并且可用于治疗和/或预防肥胖症，糖尿病，激素分泌异常，睡眠，障碍等。

9. 发明申请

US20100137391A1 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder 审中-公开
标题翻译：组胺H3激动剂用作脂质/葡萄糖代谢紊乱的治疗剂
公开(公告)号：US20100137391A1
公开(公告)日：2010-06-03
申请号：US11991859
申请日：2006-09-13
申请人： Ryo Yoshimoto , Akane Ishihara , Akio Kanatani , Shigeru Tokita
发明人： Ryo Yoshimoto , Akane Ishihara , Akio Kanatani , Shigeru Tokita
IPC分类号： A61K31/4178 , A61K31/417 , G01N33/53 , C12Q1/02 , G01N33/68 , A61P3/00 , A61P3/06 , A61P3/08
CPC分类号： G01N33/566 , A61K31/417 , A61K31/4178 , C07D233/64 , C07D403/04 , G01N2500/00
摘要： Disclosed are: novel use of an agonist histamine receptor H3 (e.g., Imetit) for prevention of obesity or the reduction of food intake; a method for evaluation of a compound for use as a therapeutic agent targeted to histamine receptor HR protein; and a compound provided by the method.
摘要翻译：公开了：用于预防肥胖或减少食物摄入的激动剂组胺受体H3（例如，Imetit）的新用途; 用作靶向组胺受体HR蛋白质的治疗剂的化合物的评价方法; 和通过该方法提供的化合物。

10. 发明授权

US07645756B2 Nitrogenous fused heteroaromatic ring derivative 失效
标题翻译：含氮稠合杂芳环衍生物
公开(公告)号：US07645756B2
公开(公告)日：2010-01-12
申请号：US10589832
申请日：2005-02-17
申请人： Toshiyuki Takahashi , Akio Kanatani , Shigeru Tokita , Ryo Yoshimoto
发明人： Toshiyuki Takahashi , Akio Kanatani , Shigeru Tokita , Ryo Yoshimoto
IPC分类号： C07D487/04 , A61K31/5025 , A61K31/53 , A61P3/04 , A61P3/10 , A61P9/10
CPC分类号： C07D487/04
摘要： The invention provides a compound or its pharmaceutically-acceptable salt of formula wherein A1 is a hydrogen, etc.; j and k are 0 or 1; is a double bond, etc.; is a double bond, etc.; one of W1 and W2 is E—O—W, etc., and the other is a hydrogen atom, etc.; E is a divalent group derived from a benzene ring, etc., by removing two hydrogen atoms therefrom; W is a group of formula (II-1): which has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for prevention or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.
摘要翻译：本发明提供了下式的化合物或其药学上可接受的盐：其中A1是氢等; j和k为0或1; “img id =”CUSTOM-CHARACTER-00001“he =”3.13mm“wi =”9.14mm“file =”US07645756-20100112-P00001.TIF“alt =”custom character“img-content =”character“img-format =“tif”/>是双键等; “img id =”CUSTOM-CHARACTER-00002“he =”3.13mm“wi =”9.48mm“file =”US07645756-20100112-P00002.TIF“alt =”custom character“img-content =”character“img-format =“tif”/>是双键等; W1和W2之一是E-O-W等，另一个是氢原子等; E是通过从其中除去两个氢原子而衍生自苯环等的二价基团; W是一组式（II-1）：其具有组胺H3受体拮抗作用或组胺H3受体反向激动作用，并且可用于预防或治疗代谢系统疾病，循环系统疾病或神经系统疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式